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not dependent on de novo NO synthesis and not related to theL-Arginine deficiency and supplementation in experimental
functional effects of l-Arg administration. In kidney transplantacute renal failure and in human kidney transplant recipients.
recipients receiving organs with a short cold ischemia time (CIT)Background. The “l-arginine paradox” refers to situations
and from young donors, that is, those with a higher likelihoodwhere l-arginine (l-Arg) supplementation stimulates nitric ox-
of a functional endothelium, early administration of l-Arg im-ide (NO) synthesis, despite saturating intracellular concentra-
proved renal function.tions. This paradox is frequently observed in acute renal failure
Conclusion. Both experimental and clinical data show that(ARF). First, the effects of l-Arg on renal function of rats with
l-Arg deficiency and endothelial dysfunction are pathomecha-ARF were studied. Based on the promising results from these
nistically relevant in ARF. The data suggest a therapeutic poten-initial studies, the second part of our study searched for a form
tial for the administration of l-Arg in ARF and kidney trans-of ARF in humans that could be studied easily under conditions
with little variance and yet was linked with endothelial dysfunc- plantation, at least in patients receiving kidneys with shorter
tion. Thus, we investigated the effects of l-Arg supplementa- CIT and from younger donors.
tion immediately after kidney transplantation in 54 patients.
Methods. In uranyl nitrate-induced ARF in rats the effects
of l-Arg and L-NNA (inhibitor of nitric oxide synthase; NOS)
In acute renal failure (ARF), mostly resulting fromon glomerular filtration rate (GFR), renal plasma flow (RPF),
renal cell injury after a toxic or ischemic insult to theblood pressure (BP) and NOx (NO2  NO3 ) excretion were
examined. Tissue l-Arg levels, NOS activities, immunodetection kidney, a defect in the l-arginine:nitric oxide (l-Arg:NO)
of NOS and superoxide dismutase (SOD), activities of nicotin- pathway has been proposed to play an important patho-
amide adenine dinucleotide phosphate (NADPH) oxidase and
genetic role [1–3]. Administration of exogenous l-Argxanthine oxidase, and nitrotyrosine immunoreactive protein
to support NO synthesis has been shown to protect the(NT-IR) were determined and compared to sham operated ani-
mals. Secondly, in a randomized, double-blind study, the effects kidney against toxic or ischemic injury [4–10]. However,
of l-Arg on GFR and RPF were investigated in 54 kidney trans- the molecular mechanism of this effect and its clinical
plant recipients, receiving IV l-Arg for three days. GFR and and possible therapeutic relevance are unclear. NO is anRPF were measured on days 1, 3, 5 and 10 by scintigraphy.
important messenger molecule with numerous physiologi-Results. In experimental ARF, decreased RPF and GFR
cal and pathological functions [11–13]. In the kidney, NOwere associated with reduced tissue l-Arg levels, endothelial
NOS-III expression, NO formation and NOx excretion. Reduc- is involved in the homeostatic regulation of glomerular,
tion in GFR, RPF and NOx excretion were reversed upon admin- vascular and tubular functions [3, 14–17]. NO is synthe-
istration of exogenous l-Arg. There also was a loss of Cu,Zn-
sized from the amino acid l-arginine (l-Arg) by the en-SOD, a key enzyme against oxidative stress, and an elevation
zyme NO synthase (NOS). There are three isoforms ofof NT-IR, an indicator of nitrosative stress and suggested
marker for pathological actions of NO. However, NT-IR was NOS, neuronal (NOS-I), inducible (NOS-II) and endo-
thelial (NOS-III) [11, 12], all of which are expressed in
the kidney [15].
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Numerous experimental data suggest that the avail-failure, peroxynitrite, superoxide, nitric oxide, l-arginine, kidney trans-
plantation. ability or biological activity of NO is reduced in ARF
[1, 2, 6–8, 17]. In vivo, the activity of the l-Arg:NOReceived for publication May 25, 2001
pathway depends on a balance between synthesis andand in revised form September 24, 2001
Accepted for publication November 13, 2001 inactivation of NO. A deficiency in the synthesis could be
due to a number of factors, in particular reduced avail- 2002 by the International Society of Nephrology
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ability of the substrate l-Arg, as suggested in hypercho- confounded by the small number of patients and were
conducted many months after surgery [34, 35].lesterolemia and diabetes mellitus [18, 19]. Alternatively,
The aim of the present study was to investigate thethe reduction in biological activity of NO could be due to
basic molecular mechanisms underlying the deficiencyincreased inactivation of NO. In certain disease states, the
of the l-Arg:NO pathway in experimental ARF, and tobioactivity of NO is markedly reduced by its reaction with
determine whether l-Arg administration under these con-superoxide anions (O2 ) yielding peroxynitrite (ONOO)
ditions can improve renal function. In addition, in a dou-[20]. ONOO, unlike NO, is highly reactive and, as an
ble-blind, randomized clinical study, we correlated thesein vivo footprint [20], nitrates protein tyrosine moieties.
findings to a form of ARF in humans that could be ana-This nitrosative stress response [21, 22] has been suggested
lyzed easily under conditions with little variance and isto be the cause of cytotoxicity in a number of toxic, ische-
linked with endothelial dysfunction. Immediately aftermic and inflammatory disease models [20]. However, it
kidney transplantation, we studied the effects of l-Argis unclear whether ONOO is the cause or a consequence
on renal function and tried to identify a possible subsetof these diseases. Endothelial cells are capable of produc-
of patients who would benefit from l-Arg treatment.ing both NO and O2 . Important cellular sources of O2
are xanthine oxidase, nicotinamide adenine dinucleotide
phosphate (NADPH) oxidase [23], and NOS, which at METHODS
sub-saturating levels of l-Arg also can generate O2 [24]. Experimental animals
Notwithstanding, cells have evolved antioxidant defense
To examine the role of the l-Arg:NO pathway in ARF,mechanisms against O2 , among them superoxide dismu-
an established model of ARF was used that inducestases (SODs) [25, 26].
endothelial and tubular damage [36]. Female Sprague-Although the use of exogenous l-Arg as a substrate
Dawley rats (N  21) weighing 264  7.0 g were anes-for NOS in experimental ARF seems promising, little is
thetized with thiobutabarbital (Inactin, 100 mg/kg, IP)known about its adverse potential since excess produc-
and placed on a thermoregulated heating board to main-tion of NO has been suggested to be associated with cyto-
tain body temperature at 37.5C. Tracheotomy was per-toxicity [17, 27, 28] involving the formation of ONOO
formed and an endotracheal tube was inserted to allow[20]. However, with respect to the suitability of NT-IR
for spontaneous breathing. The left femoral vein wasas an in vivo marker for ONOO, it was demonstrated
cannulated with a catheter for infusion of saline (0.9%recently that tyrosine nitration may not necessarily re-
NaCl) at 1.5 mL/h to replace fluid and to compensate forquire ONOO and de novo NO formation. Indeed, my-
electrolyte losses. For blood sampling and measurementeloperoxidase (MPO) can catalyze tyrosine nitration
of arterial blood pressure, the femoral artery was cannu-
from nitrite independently of ONOO [29, 30]. To our
lated and attached to a blood pressure transducer, the
knowledge, none of the previously mentioned parame- output of which was recorded on a polygraph. Following
ters of oxidative and nitrosative stress have been inves- suprapubic incision the bladder was cannulated for mea-
tigated in ARF. surement of urine flow and urine sampling. After surgery,
Beyond experimental ARF, in the early phase of kid- a period of 60 minutes was allowed for equilibration be-
ney transplantation, that is, during organ harvesting, pres- fore further experimental intervention. ARF was induced
ervation and implantation, ischemia can result in impaired by a single injection of uranyl nitrate (UN; 25 mg/kg).
renal function, too. The use of the immunosuppressant, Animals were divided into four experimental groups.
cyclosporine A (CsA), enhances graft survival but this ef- Control animals received saline (N  5); ARF animals
fect is compromised by hypertension and nephrotoxicity, received uranyl nitrate for induction of ARF either alone
suggesting endothelial dysfunction [31]. Since the pre- (ARF, N 4) or in combination with l-Arg (200 mg/kg/h;
viously mentioned effects of l-Arg in experimental ARF ARFl-Arg, N  6) or N-nitro-l-arginine (L-NNA,
are likely to be associated with endothelial dysfunction, 240 g/kg/h; ARF  L-NNA, N  6).
we hypothesized that the early administration of l-Arg At the beginning of the experiment, mean arterial
prior to and immediately after human kidney transplan- pressure (MAP) was approximately 120 mm Hg in all
tation could exert equally beneficial effects. This hypoth- groups. For the estimation of GFR, inulin clearance was
esis is supported by the observation that addition of determined by infusing saline (0.5 mL/60 min) containing
l-Arg to preservation solutions enhances graft survival 2.5% inulin (Inutest, Laevosan, Austria). GFR was cal-
[32]. Moreover, a recent animal study showed beneficial culated according to equation 1:
effects of l-Arg supplementation on renal function after
GFR  (IU · VU)/IP (Eq. 1)kidney transplantation [33]. Data from clinical studies
with l-Arg in renal transplantation also showed that where IU is the concentration of inulin in urine, VU is
l-Arg improved renal hemodynamics but only in patients the urine volume, and IP is the concentration of inulin
in plasma. For estimation of renal plasma flow (RPF), in-not receiving cyclosporine. These studies, however, are
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Nitrite/nitrate measurement
Aliquots of each plasma or urine sample were diluted
as necessary. Nitrate was then converted to nitrite by ni-
trite reductase and assayed by a modification of the Griess
method [37].
Protein immunoblotting
At the end of each experiment, kidneys were removed
and snap-frozen in liquid nitrogen. For protein extraction,
the frozen tissue was crushed in a liquid nitrogen-cooled
stainless steel mortar. The resulting powder was homoge-
nized in buffer A [tetraethylammonium (TEA) 50 mmol/L,
ethylenediaminetetraacetic acid (EDTA) 0.5 mmol/L,
leupeptin 1 mol/L, pepstatin A 1 mol/L, phenylmeth-
ylsulfonyl fluoride (PMSF) 200 mol/L and glutathione
sulfhydryl (GSH) 7 mmol/L, pH 7.5] and then centrifuged
(30 min, 10,000  g, 4C) to remove cell debris. The
supernatant fractions (S10) and resuspended pellets were
stored at 70C. Total protein concentration was deter-
mined according to Bradford [38]. For protein immuno-
blotting, samples were solubilized in Laemmli buffer (95C,
5 min). About 15 g of proteins were loaded onto 7.5%
(for NOS), 12.5% (for SOD) and 10% (for NT-IR) SDS-
polyacrylamide gels. After electrophoresis, all proteins
were transferred onto nitrocellulose membranes (Hy-
bond ECL; Amersham, Buckinghamshire, UK) with 2.5
mA/cm2 for 60 minutes in 48 mmol/L Tris buffer (pH
7.5), 39 mmol/L glycine, 0.04% SDS and 10% methanol.
Quantitative protein and even transfer in each lane was
verified by reversible protein staining of the membranes
with 0.1% Ponceau S in 5% acetic acid, and absence of
proteins in the remaining gel by Coomassie blue staining.
Membranes were first blocked with 3% non-fat dry milk
in TBS buffer (10 mmol/L Tris, pH 7.5; 150 mmol/L NaCl).
Fig. 1. Renal hemodynamics in experimental acute renal failure (ARF).
They were then incubated overnight at 4C using theData represent mean  SEM of the glomerular filtration rate (GFR),
renal plasma flow (RPF), nitric oxide (NOx) excretion and mean arterial respective primary antibodies dissolved in 3% non-fat
blood pressure (MAP) in (N  4 to 6) animals with ARF receiving no dry milk in TBS. The anti-NOS-I (rabbit; Transduction
additional treatment (), or receiving either l-Arg () or L-NNA ().
Labs, Kentucky, USA), anti-NOS-II (rabbit; Transductionl-Arg or L-NNA was administered at the time of ARF induction (in-
dicated by arrows). Statistical analysis was performed by ANOVA Lab, Lexington, KY, USA), anti-NOS-III (rabbit; Calbio-
(repeated measures); *P 	 0.05 vs. ARF and was accepted as level of chem, San Diego, CA, USA), anti-NT (monoclonal; rabbit;significance.
Biozol, New York) [20], and anti-Cu/Zn-SOD (sheep;
Calbiochem) were used in dilutions of 1:1000, 2500, 2500,
4000, and 500, respectively. This was followed by re-fusion of 1% (wt/vol) sodium para-aminohippurate (PAH;
peated washing in TBS and incubation for 60 minutesMerck, Darmstadt, Germany) was used. RPF was calcu-
at room temperature with peroxidase-conjugated anti-lated according to equation 2:
rabbit IgG from donkey in a dilution of 1:1000, or peroxi-
RPF  (UPAH · VU)/PPAH (Eq. 2) dase-conjugated anti-mouse IgG from sheep in a dilution
of 1:2000 (both Amersham), or with horseradish peroxi-where UPAH is the concentration of PAH in urine and PPAH
dase-conjugated anti-sheep IgG from donkey in a dilutionis the concentration of PAH in plasma. A priming dose of
of 1:1000 (Sigma, St. Louis, MO, USA). All antibodies3 mg inulin and 2 mg PAH was used prior to the infusion
were dissolved in TBS containing 3% non-fat dry milk.of inulin. At the indicated time points (Fig. 1), urine sam-
Membranes were again washed twice for 15 minutes withples for determination of inulin and PAH were collected
TBST buffer (10 mmol/L Tris, 150 mmol/L NaCl, 0.05%and a serum sample was taken in the midpoint of each
urine collection, to ensure steady state conditions. Tween 20; pH 7.5). Immunoreactive proteins were detected
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using an enhanced chemiluminescence kit from Amer- uid chromatography (HPLC) analysis as described previ-
sham (Braunschweig, Germany). All samples were ana- ously [39].
lyzed in duplicate.
Clinical study
Protein nitrotyrosine dot blot analysis In a randomized, double-blind exploratory study, the
Proteins were denatured by heating to 95C for five effects of intravenious l-Arg on GFR and RPF in 54
minutes in 1% sodium dodecyl sulfate (SDS) in the ab- kidney transplant recipients were investigated. The ex-
sence of mercaptoethanol. Approximately 25 g protein perimental protocol was approved by the commission
was loaded into each well of a Dot Blot template (Bio- for ethics of the Medical University Clinics of Wu¨rzburg.
Dot; Biorad, Melville, NY, USA) according to the man- Immunosuppressive therapy consisted of cyclosporine A
ufacturer’s instructions and allowed to be absorbed onto and corticosteroids. Recipients were randomly allocated
the membrane at 4C overnight. Primary anti-NT (mono- to the control (saline, N  26) or l-Arg group (N  28).
clonal anti-NT-BSA) were added to each well (dilution Patients in the l-Arg group received 0.5 g l-Arginine
1:4000) and allowed to equilibrate for one hour at 4C. hydrochloride/kg body weight over 60 minutes, starting
After repeated washing, peroxidase-conjugated anti-mouse two hours prior to surgery (renal allograft transplanta-
IgG in a dilution of 1:2000 (Amersham) was added to tion). Additionally, l-Arg was infused continuously at a
the wells and allowed to equilibrate for one hour at room dose of 0.75 g/kg body wt/day for the following three
temperature. All samples were analyzed in triplicate. days in the treatment group. Control patients received
corresponding volumes of saline. GFR [di-ethylene-Determination of NOS activity
triaminpentaacetate (DTPA) clearance] and RPF (iodoh-
Catalytic activities of NOS in kidney homogenate and ippuric acid clearance) were measured on days 1, 3, 5
supernatant fractions were assayed by the standard con- and 10 after kidney transplantation by scintigraphy. For
version of tritiated l-Arg to l-citrulline [37]. Tissue ho- determination of GFR and RPF, 200 MBq [99mTc]-DTPA
mogenates (50 L) were incubated under Vmax conditions, and 2 MBq [131I]-ortho-iodohippuric acid were adminis-
that is, for 15 minutes at 37C in a total volume of 0.1 mL tered as a bolus injection with subsequent registration
of 50 mmol/L Tris buffer (pH 7.0) containing 50 nmol/L of radioactivity after 44 and 170 minutes by single sample
calmodulin, 250mol/L cyclophosphamide, hexamethyl- algorithms. RPF was calculated by the standard method
melamine, (3-[(3-cholamidoproyl)dimethylammonio]-l- of Tauxe et al [40], GFR by that of Russell et al [41].
propane-sulfonate) (CHAPS), 5 mol/L flavin adenine
dinucleotide (FAD), 5 mol/L flavin mononucleotide Statistical analysis
(FMN), 1 mmol/L NADPH, 0.7 mol/L CaCl2, 7 mmol/L All results are expressed as means  standard errorGSH, 30 mol/L l-Arg and 10 mol/L H4biopterin. For of the mean (SEM). For the animal study, differencesdetection of NOS-II activity, CaCl2 was omitted from between groups were analyzed using analysis of variancethe assay buffer and replaced by 0.5 mmol/L EDTA. All
(ANOVA, repeated measure). Point by point analysessamples were analyzed in triplicate.
were performed using the Student t test (paired or un-
paired). For the clinical study, differences between theSuperoxide production
groups were analyzed using Mann-Whitney Rank SumNADPH oxidase and xanthine oxidase activities in
test or Student t test as appropriate. A probability valuekidney homogenate were measured at 37C in a final vol-
P 	 0.05 was considered statistically significant.ume of 1 mL by lucigenin-induced, SOD inhibitable lumi-
nescence in 50 mmol/L phosphate buffer (pH 7.0) con-
taining 1 mmol/L EDTA, 150 mmol/L sucrose, 500 mol/L RESULTS
lucigenin, in the absence or presence of either 1 mmol/L
Renal function in experimental ARFNADPH or xanthine. SOD inhibitors were not included.
Uranyl nitrate-induced ARF resulted in a time-depen-The reaction was started by the addition of 100 g of
dent reduction of GFR and RPF (Fig. 1). During the courseprotein (per 100L homogenate) to 900L of the above-
of the experiment, which in total lasted about sevenmentioned freshly prepared reagent mixture. Lumines-
hours, a slight but non-significant decline in mean arterialcence was monitored every 15 seconds for 15 minutes in
pressure (MAP) was observed. The values for MAP werea luminometer (Lumat LB 9501; Berthold, Mu¨nchen,
not significantly different between animals receiving ei-Germany). No activity could be measured in the absence
ther l-Arg or the NOS-inhibitor L-NNA. While NOS-of NADPH, or was beyond detection limit with lucigenin
inhibitors did not cause an increase in blood pressure inconcentrations 	500 mol/L.
this study, this was probably negated by other mecha-
Determination of L-Arg levels by HPLC nisms in ARF such as stimulation of the renin-angioten-
sin system, enhanced sympathetic activity and elevationl-Arginine measurements in S10 fractions of rat kid-
ney were performed by reversed-phase high-pressure liq- of circulating catecholamines. Nevertheless, both com-
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Table 1. Tissue l-arginine (l-Arg) levels in control and acute renal
failure (ARF) animals with and without l-Arg administration
Treatment Tissue l-Arg
N lmol/L Changes in % of control
Control 5 24.20.4
ARF 4 18.60.8a 233.3
ARFl-Arg 6 37.25.7ab 5424
Results were analysed by the Student t test (unpaired).
a Significant difference versus control (P 	 0.05)
b Significant different versus ARF animals (P 	 0.05)
pounds affected intrarenal NO metabolism, since l-Arg
increased whereas L-NNA decreased NOx excretion.
Treatment with l-Arg significantly improved GFR and
RPF, while treatment with l-NNA produced a further
fall in these parameters. d-Arg has been shown to have
no effects on these parameters in the same model of ARF
(data not shown). Therefore an additional treatment
group with d-Arg was avoided to keep number of experi-
Fig. 2. Immunodetection of nitric oxide synthase (NOS) and superoxide
mental animals low. dismutase (SOD) in control and ARF animals. Kidneys were homoge-
nized in buffer A and centrifuged at 10,000  g (S10). Proteins were
separated by electrophoresis and transferred onto a nitrocellulose mem-Tissue L-Arg levels and NOS expression in
brane. Membranes were incubated with primary antibodies againstexperimental ARF
NOS-I, NOS-II, NOS-III and Cu,Zn SOD, followed by incubation with
the respective peroxidase-conjugated or horseradish-conjugated IgG.Since the previously mentioned results demonstrated
Immunoreactive proteins were detected by enhanced chemilumines-a deficiency in the l-Arg:NO pathway in ARF, we at-
cence as described in the Methods section. Cytosolic Cu,Zn SOD (Cu,Zn
tempted to elucidate further the molecular mechanism SOD, cyt.) and extracellular Cu,Zn SOD (Cu,Zn SOD, e.c.) were de-
tected from the pellet and S10 fractions of kidney samples, respectively.involved by investigating whether tissue l-Arg levels or
Control and ARF data for each antigen were from the same blot. DataNOS expression were altered. We observed that the tissue
are representative of 4 to 6 animals, each analyzed in duplicate.
l-Arg levels in ARF animals, as measured by HPLC anal-
ysis, were indeed significantly reduced when compared
to control (sham-treatment) animals. This effect was re- xanthine oxidase activity was not different in control and
versed by the administration of l-Arg (Table 1). While ARF animals (Fig. 3). While these data argued against
the percentage of reduction in tissue l-Arg levels appeared oxidative stress responses in ARF, NT-IR, an indicator
to be small, it was nevertheless of functional relevance of nitrosative stress and suggested marker for ONOO
or restricted to a compartment of the kidney that is mediated cytotoxicity [20], was increased (Fig. 4B). The
essential for NO synthesis as excretory NOx levels corre- consequences of this are unclear, as the protein most
lated to improvement of renal function with l-Arg (Fig. 1). affected by ONOOwas serum albumin, as evidenced by
In addition, ARF caused a loss in NOS-III immunore- immunoprecipitation analysis (Fig. 4A). Thus, tyrosine
activity without affecting NOS-I or NOS-II protein ex- nitration may occur predominantly in the extracellular
pression (Fig. 2). However, the total NOS activity was space, presumably at the intravascular lumen. Most im-
not significantly altered in ARF. These results suggest portantly, NT-IR was not affected by the administration
that NOS-III contributed only a minor part of total kid- of l-Arg or L-NNA (Fig. 4B), suggesting that exogenous
ney NOS-activity, and that ARF involves a specific com- l-Arg per se did not cause an increase in nitrosative
partment of the kidney that is affected by both reduced stress and its effects were not mediated by preventing
NOS-III expression and l-Arg levels, presumably the the uncoupling of NO synthase. Thus, possible cytotoxic
vascular endothelium. side effects of an l-Arg treatment through ONOO for-
mation are unlikely. Insufficient removal of O2 , on the
NO, O2 and ONOO other hand, may have contributed to the observed in-
In addition to decreased NO synthesis, a functional de- crease in NT-IR. In accordance with this hypothesis,
fect in the l-Arg:NO pathway also may arise from in- expression of Cu,Zn-SOD, in particular that of the extra-
creased NO breakdown. Since the reaction of NO with cellular type, was significantly decreased in ARF as com-
O2 represents an important mechanism herein, we inves- pared to control animals (Fig. 2). Similar results were
tigated the enzymatic activities of two important O2 - obtained for total Mn-SOD-IR; however, due to consid-
generating enzymes, NADPH and xanthine oxidase. erable proteolysis of Mn-SOD these data are difficult to
interpret (data not shown).NADPH oxidase activity appeared to be decreased, and
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Fig. 3. NADPH oxidase and xanthine oxidase activity in ARF. Rats
from control () and ARF animals () were analyzed for NADPH
oxidase and xanthine oxidase activities. Data are mean  SEM of 4 to
6 experiments, each analyzed in triplicate. There was no O2 production
in the absence of NADPH.
Clinical data
In a randomized double-blind study, 54 kidney trans-
plant recipients were divided into two groups: one re-
ceived l-Arg and the other received saline (Methods
section). The patients’ characteristics are described in
Table 2. l-Arg was administered two hours prior to sur-
gery and continuously infused for an additional three
days. GFR and RPF, monitored by scintigraphy for up Fig. 4. Nitrotyrosine immunoreactivity (NT-IR) in control and ARF
animals. (A) NT-IR was detected by immunoblotting using both mono-to 10 days after surgery, gradually improved during that
clonal (mAb) and polyclonal (pAb) anti-NT antibodies [11]. In sometime in both groups (Table 3). Moreover, GFR and RPF
experiments, protein was extracted by immunoprecipitation with anti-
were better improved in the l-Arg treated group as com- bovine serum albumin (anti-BSA IP) and then analyzed for NT-IR.
(B) Densitometric quantification of NT-IR from control (N  5) andpared to control groups (from day 1 to day 5; however,
ARF animals (N  4). Quantification is given in arbitrary absorbancethis did not reach statistical significance). These trends
units (AU). S10 refers to the 10,000  g supernatant fractions of total
were reversed at day 10 post-surgery (Table 3), that is, kidney homogenate. Results were analyzed by the Student t test (un-
paired); *P 	 0.05 vs. control animals and was accepted as level ofseven days after l-Arg treatment was stopped, suggesting
significance.that l-Arg indeed improved suppressed renal function
in the early phase of kidney transplantation. To analyze
further whether a specific subset of patients particularly
33  6 mL/min) this increase did not reach statisticalbenefitted from l-Arg treatment, GFR and RPF at day 3
significance. These effects were associated with increased(after day 3 l-Arg infusion was stopped) were correlated
plasma NOx levels at day 1 for the group with donor ageagainst several parameters [NOx, cGMP, donor sex, dis-
	45 years (43 4 vs. 78 22 mol/L) and with CIT lessease stage, HLA-mismatches, organ donor age and cold
than 20 hours (43 4 vs. 69 14mol/L). Because of theischemia time (CIT)]. However, only organ donor age
high variance of NOx values, however, these differencesand CIT were found to affect the outcome after l-Arg
were not significant. There was no correlation betweenadministration (Fig. 5 A–D). Indeed, in patients receiv-
cold ischemia time and donor age in the control (P ing kidneys with CITs below 20 hours or from donors
0.60; r2 0.12) and L-Arg-group (P  0.58; r2  0.14).
younger than 45 years of age l-Arg increased RPF when
compared to the saline-treated control group (Fig. 5
DISCUSSIONE, F). Also, GFR on day 1 was increased for patients
with CIT less than 20 hours (20  3 vs. 32  5 mL/min, The present study provides several molecular mecha-
nism for the relative deficiency in the l-Arg:NO pathwayP 	 0.05), for donors younger than 45 years (20  3 vs.
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Fig. 5. Effect of L-Arg in renal transplant patients. (A, B) Linear regression analysis of the relationship between donor age and the effect of l-Arg
on renal plasma flow (RPF). (C, D) Linear regression analysis of the relationship between the duration of cold ischemia time (CIT) and the effect
of l-Arg on RPF. There was no significant correlation in the control group (A, C), but there was a significant negative correlation in the l-Arg
treatment group (B, D). (E ) Mean data  SEM for RPF when including recipients with donor age 	45 years in control (N  16) and l-Arg
treated groups (N  15). (F ) Mean data  SEM for RPF when including recipients with duration of cold ischemia time 	20 hours in the control
(N  19) and l-Arg treated groups (N  16). Symbols are: () control group; () l-Arg treated group. l-Arg was infused from day 1 to day 3.
Differences between control and l-Arg treatment were analyzed by the unpaired Student t test; NS indicates not significant; *P 	 0.05 compared
to control, which was accepted as level of significance.
and endothelial dysfunction in both experimental ARF of the l-Arg pool and the caveolar localized endothelial
NOS. Several other mechanisms also have been put for-and in the early stage of kidney transplantation. In exper-
imental ARF, reduced GFR and RPF were associated ward. Firstly, it has been found that the expression and
distribution of cationic amino Y transporter (CAT),with a deficiency in tissue l-Arg, reduced NOS-III ex-
pression and consequently NOx excretion. The functional which is responsible for approximately 70% of all l-Arg
transported into cells, is co-localized with NOS in caveo-consequences of this were reversed by l-Arg administra-
tion and exacerbated by the addition of the NOS inhibi- lae [43]. At present, it is unknown whether the expression
of CAT is altered in disease states. However, a decreasetor L-NNA. The respective D-isomers are ineffective in
this model of ARF (data not shown). The fall in tissue in CAT activity or expression could alter the rate of l-Arg
transport into vascular endothelial cells. This could ex-l-Arg levels is thus of pathomechanistic and therapeutic
relevance. This explanation, however, is difficult to rec- plain the protective effect of l-Arg administration by
improving l-Arg uptake. Secondly, l-Arg administrationoncile with the fact that l-Arg concentrations within
entire tissue exceeds the Km value for endothelial NOS can overcome the activity of endogenous inhibitors of
NOS such as asymmetric dimethyl arginine (ADMA)(5 mol/L) by far [42]. It is therefore perplexing why
the administration of l-Arg augmented the formation of and methylguanidine, which have been shown to be in-
creased in hypercholesterolemic humans and in patientsNO and excretion as NOx, while a reduction in tissue
l-Arg by only 23% impaired it. Although plasma levels with end-stage renal failure [44, 45]. Although doubts
have been raised about whether the level of ADMAof L-arginine could give additional information, it has
been found that plasma levels can be misleading; NO within cells can become high enough to effectively com-
pete with l-Arg for NOS, it was reported recently thatformation is affected and augmented by supplying argi-
nine despite—theoretically—saturating arginine plasma dialysis-related hypotension in end-stage renal failure pa-
tients was associated with removal of ADMA from thelevels (the so-called “arginine-paradox”). This paradox
has been explained by subcellular compartmentalization circulation [46]. A third possibility is that l-Arg deficiency
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Table 3. Effects of l-Arg on GFR and RPF in kidneyTable 2. Clinical features of randomized kidney transplant
recipients (N54) transplant recipients
Treatment Day 1 Day 3 Day 5 Day 10Characteristics Control l-Arg
Number of patients 26 28 GFR mL/min Control 232 273 313 404
l-Arg 263 314 334 384Sex (male1, female0) 0.650.09 0.650.09
Age of recipients years 49.42.33 45.61.94 RPF mL/min Control 14214 19128 18822 20924
l-Arg 15821 22231 21929 17722Age of donor years 39.52.98 40.32.83
Body weight kg 72.82.64 712.58 Mean data showing glomerular filtration rate (GFR) and renal plasma flow
Duration of warm ischemia min 41.21.82 40.61.99 (RPF) in kidney transplant recipients from control (N 26) and l-Arg treatment
Duration of cold ischemia h 19.40.99 19.40.66 group (N  28). l-Arg was infused from day 1 to day 3. Results were expressed
Duration of dialysis years 3.30.35 4.30.52 as mean  SEM. There were no significant differences between the control and
l-Arg groups.None of the differences between control group and l-Arg group was significant.
caused an uncoupling of NOS, resulting in O2 formation Our experimental findings may be translated to the
instead of NO. This could then affect not only total clinical situation of impaired kidney function in renal
NO production but also, via metabolism to ONOO, its transplant patients co-medicated with CsA. Here, an en-
bioactivity. dothelial dysfunction also appears to play an important
Indeed, our finding that NT-IR was dramatically in- pathophysiological role. l-Arg significantly improved re-
creased in ARF animals suggests that the bioavailabil- nal function in that subset of organ recipients (young
ity of NO was altered by scavenging through O2 . How- donor age and short CIT) with the highest likelihood of
ever, importantly, we found that increased NT-IR was functional endothelium, thereby making it possible for
not due to an increase in known prominent cellular sources l-Arg to augment vascular NO synthesis. This finding is
of O2 production (xanthine and NADPH oxidase) and at variance with previous studies showing no effect of
was independent of de novo NO synthesis, arguing against l-Arg on renal function in kidney transplant patients on
intermediate ONOO formation as the underlying mech- CsA treatment. However, these studies were conducted
anism. Conversely, the increase in NT-IR in ARF was
many months after kidney transplantation [34, 35]. More-
most likely due to a lack of antioxidative defense, that
over, the number of patients engaged in these studiesis, reduced SOD expression. Clearly, a more proteomic
was too small (that is, between 6 and 10 patients perapproach including all SODs, catalase, all glutathione
group) to perform subgroup analyses, possibly obliterat-reductases and thioredoxin would be desirable, but is
ing the protective effects of l-Arg. Donor age has beenbeyond of the scope of this investigation. Unequivocal
excluded as an important parameter of successful kidneyevidence for the functional importance of SODs in mam-
transplantation [50], while the role of CIT is controver-malian cells has been provided by studies using trans-
sial [51, 52]. However, in our exploratory study, in thegenic mice over-expressing different SOD genes [47, 48].
presence of sufficient l-Arg RPF improved both in pa-Transgenic mice carrying human SOD genes were more
tients with shorter CIT and with organs from young do-resistant to toxic oxygen exposure compared to wild-type
nors. Also, GFR improved, however, statistical signifi-animals [47, 48]. However, the mechanism by which the
expression of SOD, in particular the extracellular type cance was reached only in patients with a CIT less than
and possibly Mn-SOD, were down-regulated in this 20 hours. This may be of clinical relevance and—in con-
model are unknown and await further investigation. Al- text with the experimental results from ARF—calls for
ternatively, the increased NT-IR levels in ARF may be a critical evaluation of the effects of L-Arg on impaired
derived from nitrogen sources other than newly synthe- renal function in kidney transplant recipients and ARF
sized NO, such as NO2 . This could be the consequence in general.
of either the action of myeloperoxidase, which generates
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